inzulinfügg

Inzulinfügg denotes insulin dependence: the need for regular insulin to regulate blood glucose. It is most closely associated with insulin-dependent diabetes, typically type 1, where the body cannot produce sufficient insulin. Some people with type 2 diabetes or gestational diabetes may also become insulin-dependent if other treatments fail to maintain glucose control.

Insulin therapy replaces or supplements natural insulin. It is delivered by injections or continuous subcutaneous infusion via an insulin pump. Dosing often follows a basal-bolus pattern, with long-acting insulin providing a constant background level and rapid- or short-acting insulin taken with meals to manage postprandial spikes. Insulin preparations vary by onset and duration.

Management includes regular blood glucose monitoring, carbohydrate counting, and dose adjustments based on activity, illness, and diet. Education on recognizing hypoglycemia and hyperglycemia, storage of insulin, and proper administration is essential. Technology such as continuous glucose monitors and pumps can improve control and reduce episodes of low blood sugar.

Historical context: insulin was discovered in 1921, transforming a previously fatal disease into a manageable condition. Today, many individuals remain insulin-dependent for life. Potential risks include hypoglycemia, ketoacidosis during insulin deficiency, and long-term complications such as retinopathy, nephropathy, neuropathy, and cardiovascular disease when glucose control is suboptimal.

The term "inzulinfügg" is used in various languages to describe this dependence. In English, it corresponds to insulin dependence or insulin-dependent diabetes mellitus (IDDM). Related topics include diabetes mellitus, insulin therapy, glycemic monitoring, and diabetes complications.